Amprion develops assay technology that allows for ultra-sensitive detection of misfolded proteins in biological samples such as serum or urine. The company's technology involves proprietary Protein Misfolding Cyclic Amplification (PMCA). The goal is to detect disease-relevant misfolded protein species prior to the onset of clinical disease symptoms. PMCA recapitulates in vitro the protein aggregation process ongoing during the development of neurodegenerative disorders such as Alzheimer's Disease, Parkinson's disease, and Prion diseases. The technology can be adapted to a variety of misfolded protein species, including A?, tau, alpha-synuclein and PrP.
